BGLC
BioNexus Gene Lab·NASDAQ
--
--(--)
--
--(--)
BGLC fundamentals
During Q3 2025, BioNexus Gene Lab (BGLC) reported revenue of 2.54M, a YoY change of -3.29%. Net income was -708.99K, a YoY change of 47.30%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 3.25M -- | 3.03M -- | 2.49M -- | 2.58M -- | 2.84M -12.50% | 2.38M -21.52% | 2.57M +3.29% | 2.55M -0.83% | 2.27M -19.95% | 2.38M +0.20% | 1.97M -23.07% | 2.63M +3.00% | 2.52M +11.03% | 2.14M -10.28% | 2.26M +14.47% | 2.54M -3.29% | 9.47M -- |
Sales and Services Revenue | 3.25M -- | 3.03M -- | 2.49M -- | 2.58M -- | 2.84M -12.50% | 2.38M -21.52% | 2.57M +3.29% | 2.55M -0.83% | 2.27M -19.95% | 2.38M +0.20% | 1.97M -23.07% | 2.63M +3.00% | 2.52M +11.03% | 2.14M -10.28% | 2.26M +14.47% | 2.54M -3.29% | 9.47M -- |
Cost of Revenue | 2.84M -- | 2.67M -- | 2.22M -- | 2.28M -- | 2.50M -12.00% | 2.01M -24.86% | 2.23M +0.27% | 2.20M -3.35% | 2.01M -19.75% | 2.02M +0.42% | 1.69M -24.30% | 2.30M +4.75% | 2.21M +10.37% | 1.79M -11.07% | 1.89M +12.24% | 2.17M -5.98% | 8.07M -- |
Cost of Goods and Services | 11.10M -- | -- -- | -- -- | -- -- | 9.67M -12.85% | -- -- | -- -- | 2.20M -- | 2.01M -79.25% | 2.02M -- | 1.69M -- | 2.30M +4.75% | 2.21M +10.37% | 1.79M -11.07% | 1.89M +12.24% | 2.17M -5.98% | 8.07M -- |
Cost of Financing Services | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 0 -- | -- -- |
Gross Profit | 477.17K -- | 356.33K -- | 263.97K -- | 299.50K -- | 339.23K -28.91% | 368.90K +3.53% | 339.71K +28.69% | 354.33K +18.31% | 266.56K -21.42% | 365.03K -1.05% | 288.72K -15.01% | 326.54K -7.84% | 309.23K +16.01% | 343.49K -5.90% | 368.02K +27.47% | 377.69K +15.66% | 1.40M -- |
Other Operating Income | 66.49K -- | -- -- | -- -- | -- -- | 179.28K +169.63% | -- -- | -- -- | 199.28K -- | -155.84K -186.92% | 134.93K -- | -- -- | -- -- | 167.29K +207.35% | 42.70K -68.35% | -- -- | -- -- | -- -- |
Operating Expenses | 342.60K -- | 321.64K -- | 401.94K -- | 364.71K -- | 641.20K +87.16% | 419.53K +30.43% | 611.91K +52.24% | 3.08M +745.08% | -16.95K -102.64% | 607.97K +44.92% | 703.52K +14.97% | 2.13M -30.90% | -288.96K -1604.30% | 1.03M +69.12% | 1.14M +61.73% | 1.19M -44.22% | 3.06M -- |
Selling, General and Administrative Expenses | 182.83K -- | 368.04K -- | 454.78K -- | 418.82K -- | 487.86K +166.84% | 536.87K +45.87% | 807.08K +77.46% | 3.08M +635.90% | -1.39M -384.17% | 469.67K -12.52% | 695.32K -13.85% | 2.04M -33.88% | 801.79K +157.83% | 932.57K +98.56% | 1.13M +61.83% | 997.26K -51.06% | 3.86M -- |
Selling and Marketing Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 596.86K -- | 153.87K -- | 136.49K -- | 1.25M -- | 494.86K -17.09% | 540.70K +251.39% | 608.43K +345.75% | 551.57K -55.71% | 2.20M -- |
General and Administrative Expenses | 1.28M -- | -- -- | -- -- | -- -- | 1.73M +35.37% | -- -- | -- -- | 3.08M -- | -1.98M -214.67% | 315.79K -- | 558.83K -- | 792.41K -74.29% | 306.93K +115.48% | 391.88K +24.09% | 516.79K -7.52% | 445.69K -43.76% | 1.66M -- |
Research and Development Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 54.98K -- | 11.47K -- | 8.20K -- | 10.44K -- | 17.40K -68.36% | 12.14K +5.79% | 12.56K +53.17% | 14.88K +42.46% | 56.97K -- |
Loss on Bad Debts | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 1.31M -- | 88.72K -- | 0 -- | 2.37K -- | -928.72K -170.66% | 14.97K -83.12% | 0 -- | 175.82K +7305.98% | -737.93K -- |
Loss on Disposal of Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -6.18K -- | -- -- | -- -- | -- -- | 0 +100.00% | -- -- | -- -- | -- -- |
Other Operating Expenses | 159.76K -- | -46.39K -- | -52.85K -- | -54.11K -- | 153.34K -4.02% | -117.34K -152.93% | -195.16K -269.29% | -- -- | -- -- | 44.30K +137.75% | -- -- | 79.00K -- | -179.43K -- | 68.50K +54.63% | -- -- | -- -- | -- -- |
Operating Income | 201.06K -- | 34.69K -- | -137.96K -- | -65.22K -- | -122.69K -161.02% | -50.63K -245.95% | -272.20K -97.30% | -2.53M -3777.19% | 127.67K +204.06% | -108.01K -113.33% | -414.80K -52.39% | -1.80M +28.69% | 765.49K +499.58% | -641.99K -494.37% | -769.75K -85.57% | -810.27K +55.06% | -1.46M -- |
Non-Operating Income (Loss) | -3.99K -- | -3.33K -- | -2.32K -- | -2.07K -- | -4.76K -19.47% | -2.44K +26.49% | -3.04K -31.18% | -4.26K -105.55% | 125.90K +2743.87% | 24.32K +1094.76% | 669.49K +22108.19% | 459.33K +10885.02% | -1.19M -1043.22% | 18.66K -23.28% | 153.58K -77.06% | 101.28K -77.95% | -914.00K -- |
Gain (Loss) on Other Investment | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 20.00K -- | 59.63K -- | -94.75K -- | -- -- | 8.63K -56.87% | 46.57K -21.90% | -- -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 32.40K -- | 69.77K -- | -243.08K -- | -- -- | -27.26K -184.15% | -- -- | -- -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 571.84K -- | 301.11K -- | -945.90K -- | -- -- | 147.32K -74.24% | 40.41K -86.58% | -- -- |
Net Interest Expense | 3.99K -- | 3.33K -- | 2.32K -- | 2.07K -- | 4.76K +19.47% | 2.44K -26.49% | 3.04K +31.18% | 4.26K +105.55% | -125.90K -2743.87% | -24.32K -1094.76% | -45.26K -1587.80% | -28.83K -776.90% | -96.22K +23.58% | -18.66K +23.28% | -24.89K +45.01% | -14.30K +50.41% | -154.06K -- |
Interest Expense | 3.99K -- | 3.33K -- | 2.32K -- | 2.07K -- | 4.76K +19.47% | 2.44K -26.49% | 3.04K +31.18% | 4.26K +105.55% | 4.18K -12.16% | 4.66K +90.63% | 4.48K +47.27% | 6.19K +45.41% | 5.81K +38.94% | 4.91K +5.32% | 4.88K +8.91% | 6.48K +4.67% | 22.08K -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 130.08K -- | 28.98K -- | 49.74K -- | 35.02K -- | 102.03K -21.57% | 23.57K -18.68% | 29.77K -40.15% | 20.78K -40.67% | 176.14K -- |
Pretax Income From Continuing Operations | 197.08K -- | 31.36K -- | -140.28K -- | -67.29K -- | -127.45K -164.67% | -53.08K -269.22% | -275.24K -96.20% | -2.53M -3664.13% | 253.57K +298.96% | -83.69K -57.68% | 254.69K +192.53% | -1.34M +46.94% | -422.03K -266.44% | -623.33K -644.81% | -616.17K -341.93% | -708.99K +47.24% | -2.37M -- |
Income Tax Expense | 107.83K -- | 14.30K -- | -1.62K -- | 10.11K -- | 29.52K -72.63% | 15.99K +11.83% | -15.99K -886.43% | 76.42K +655.57% | -54.89K -285.96% | 20.07K +25.50% | 55.58K +447.62% | 1.55K -97.97% | -73.71K -34.29% | -- -- | -- -- | -- -- | -- -- |
Current Income Tax | 264.55K -- | -- -- | -- -- | -- -- | 48.41K -81.70% | -- -- | -- -- | -- -- | 38.88K -19.68% | -- -- | -- -- | -- -- | 15.80K -59.37% | -- -- | -- -- | -- -- | -- -- |
Deferred Income Tax | 26.74K -- | -- -- | -- -- | -- -- | 3.90K -85.42% | -- -- | -- -- | -- -- | -17.36K -545.33% | -- -- | -- -- | -- -- | -12.30K +29.11% | -- -- | -- -- | -- -- | -- -- |
Net Income | 89.24K -- | 17.07K -- | -138.66K -- | -77.40K -- | -156.97K -275.89% | -69.07K -504.70% | -259.25K -86.97% | -2.61M -3271.00% | 308.46K +296.51% | -103.76K -50.23% | 199.10K +176.80% | -1.35M +48.44% | -348.32K -212.92% | -623.33K -500.76% | -616.17K -409.47% | -708.99K +47.30% | -2.30M -- |
Net Income Attributable to Owners of the Company | 89.24K -- | 17.07K -- | -138.66K -- | -77.40K -- | -156.97K -275.89% | -69.07K -504.70% | -259.25K -86.97% | -2.61M -3271.00% | 308.46K +296.51% | -103.76K -50.23% | 199.10K +176.80% | -1.35M +48.44% | -348.32K -212.92% | -623.33K -500.76% | -616.17K -409.47% | -708.99K +47.30% | -2.30M -- |
Net Income Attributable to Common Stockholders | 89.24K -- | 17.07K -- | -138.66K -- | -77.40K -- | -156.97K -275.89% | -69.07K -504.70% | -259.25K -86.97% | -2.61M -3271.00% | 308.46K +296.51% | -103.76K -50.23% | 199.10K +176.80% | -1.35M +48.44% | -348.32K -212.92% | -623.33K -500.76% | -616.17K -409.47% | -708.99K +47.30% | -2.30M -- |
Other Comprehensive Income | 38.93K -- | -68.78K -- | -317.76K -- | -320.59K -- | 398.33K +923.19% | -39.04K +43.24% | -333.89K -5.08% | -18.60K +94.20% | 123.30K -69.05% | -209.91K -437.69% | 2.46K +100.74% | 1.05M +5726.99% | -717.05K -681.54% | 72.16K +134.38% | 367.08K +14803.69% | 3.22K -99.69% | -274.60K -- |
Total Comprehensive Income | 128.17K -- | -51.71K -- | -456.42K -- | -397.99K -- | 241.36K +88.31% | -108.11K -109.06% | -593.14K -29.95% | -2.63M -560.26% | 431.76K +78.89% | -313.67K -190.15% | 201.57K +133.98% | -298.58K +88.64% | -1.07M -346.75% | -551.17K -75.72% | -249.09K -223.58% | -705.77K -136.38% | -2.57M -- |
Total Comprehensive Income Attributable to Owners of the Company | 128.17K -- | -51.71K -- | -456.42K -- | -397.99K -- | 241.36K +88.31% | -108.11K -109.06% | -593.14K -29.95% | -2.63M -560.26% | 431.76K +78.89% | -313.67K -190.15% | 201.57K +133.98% | -298.58K +88.64% | -1.07M -346.75% | -551.17K -75.72% | -249.09K -223.58% | -705.77K -136.38% | -2.57M -- |
Basic EPS | -- -- | 0 -- | 0 -- | -0.03 -- | -- -- | -0.01 -- | -0.04 -- | -0.16 -433.33% | 0.02 -- | -0.01 -- | 0.11 +375.00% | -0.75 -368.75% | -0.02 -200.00% | -0.04 -300.00% | -0.34 -409.09% | -0.39 +48.00% | -0.79 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.16 -- | -- -- | -0.01 -- | 0.11 -- | -0.75 -368.75% | -- -- | -0.04 -300.00% | -0.34 -409.09% | -0.39 +48.00% | -- -- |
Diluted EPS | -- -- | 0 -- | 0 -- | -0.03 -- | -- -- | -0.01 -- | -0.04 -- | -0.16 -433.33% | -- -- | -0.01 -- | 0.11 +375.00% | -0.75 -368.75% | -- -- | -0.04 -300.00% | -0.34 -409.09% | -0.39 +48.00% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.16 -- | -- -- | -0.01 -- | 0.11 -- | -0.75 -368.75% | -- -- | -0.04 -300.00% | -0.34 -409.09% | -0.39 +48.00% | -- -- |
You can ask Aime
What guidance did BioNexus Gene Lab's management provide for the next earnings period?Did BioNexus Gene Lab beat or miss consensus estimates last quarter?What is the market's earnings forecast for BioNexus Gene Lab next quarter?What were the key takeaways from BioNexus Gene Lab’s earnings call?What factors drove the changes in BioNexus Gene Lab's revenue and profit?What is the revenue and EPS growth rate for BioNexus Gene Lab year over year?What were the key takeaways from BioNexus Gene Lab's earnings call?What does BioNexus Gene Lab do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
